Laiko General Hospital Of Athens
- Address
- Messogion Avenue 152, 115 27 Athens, Greece
Laiko General Hospital Of Athens - Advanced Clinical Research Center
Laiko General Hospital of Athens stands as a premier clinical research institution, conducting cutting-edge trials across multiple therapeutic areas with particular expertise in immunology, rheumatology, and hematology. The center has established itself as a key contributor to international multi-center studies, focusing on breakthrough therapies for autoimmune diseases, cardiovascular conditions, and rare genetic disorders.
- Autoimmune and Rheumatic Diseases: Active trials in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, and lupus nephritis investigating novel JAK inhibitors, TYK2 inhibitors, and immunomodulatory agents
- Hematologic Disorders and Oncology: Research in hemophilia B gene therapy, hemophilia management, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and hereditary angioedema
- Cardiovascular and Metabolic Research: Studies evaluating novel anticoagulants for stroke prevention in atrial fibrillation, cardiovascular outcomes in obesity, and diabetes management with next-generation therapies
- Oncology Immunotherapy: Advanced melanoma trials investigating combination immunotherapy approaches and personalized cancer vaccine strategies
The hospital demonstrates particular strength in rare disease research including IgA nephropathy and hereditary angioedema, as well as comprehensive programs for inflammatory conditions such as axial spondyloarthritis and idiopathic inflammatory myopathy. With participation in Phase 2b through Phase 4 clinical trials, Laiko General Hospital contributes valuable data on both emerging therapies and long-term safety profiles of established treatments, supporting the development of transformative medical interventions for patients with serious and life-threatening conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 22 therapeutic areas and 15 of 476 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 468 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 72 by active trials.
- 1Merck Sharp & Dohme LLC23active
lock +71 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC36trials
lock +47 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Laiko General Hospital Of Athens
lock Showing 1 of 373 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 40-Week Randomized Study Evaluating the Efficacy and Safety of Weekly Insulin Icodec/Semaglutide Versus Daily Insulin Glargine in Type 2 Diabetes Patients | Novo Nordisk A/S | Phase III | Not Recruiting | Feb 2024 | Jun 2025 |
IMP list
lock Showing 1 of 476 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 45 | Unknown | 2015-11-06 | 2026-06-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.